This approach prioritizes targeted, nutrient-based care to help individuals maintain their vision and quality of life
As the first oral GLP-1 approved for weight loss , the newly-approved Wegovy pill ( semaglutide ) is an exciting alternative for people who may be apprehensive about injections or would prefer an oral medication
Regular follow-up schedule during maintenance therapy typically includes: Clinical visits every 3-6 months to assess weight trends, side effects, and comorbidity status Laboratory monitoring as clinically indicated (lipid panel, hemoglobin A1c if diabetic, liver function tests if indicated) Blood pressure monitoring given expected improvements with weight loss Nutritional assessment to ensure adequate protein and micronutrient intake during weight loss Patients should be empowered to contact their healthcare provider between scheduled visits if concerning symptoms develop, including persistent gastrointestinal symptoms, signs of gallbladder disease, severe abdominal pain, or symptoms of hypoglycemia
Neither is currently licensed for routine clinical use in the UK
A quarter of an avocado
GLP-1RAs activate GLP-1R similarly to GLP-1, but they are resistant to the activity of DPP-4